POINT Biopharma Global (NASDAQ:PNT) Trading Down 9.6%

POINT Biopharma Global Inc. (NASDAQ:PNT)’s share price traded down 9.6% during mid-day trading on Monday . The company traded as low as $10.18 and last traded at $10.18. 2,125 shares were traded during mid-day trading, a decline of 98% from the average session volume of 102,823 shares. The stock had previously closed at $11.26.

PNT has been the subject of a number of recent analyst reports. Piper Sandler initiated coverage on POINT Biopharma Global in a report on Monday, July 26th. They set an “overweight” rating and a $17.00 target price for the company. Jefferies Financial Group initiated coverage on POINT Biopharma Global in a report on Tuesday, July 27th. They set a “hold” rating and a $8.00 target price for the company. Finally, Cowen initiated coverage on POINT Biopharma Global in a report on Thursday, July 29th. They set an “outperform” rating for the company.

The firm has a fifty day moving average price of $9.17.

POINT Biopharma Global (NASDAQ:PNT) last issued its quarterly earnings data on Thursday, August 12th. The company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. Sell-side analysts predict that POINT Biopharma Global Inc. will post -0.69 EPS for the current year.

POINT Biopharma Global Company Profile (NASDAQ:PNT)

POINT Biopharma Global Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of radioligand therapies for the treatment of cancer. Its products include PNT2001, a PSMA radioligand that is in preclinical studies for early stage prostate cancer treatment; PNT2002, which is in Phase 3 studies to evaluate superiority to the standard of care in mCRPC patients; PNT2003, a somatostatin-targeted radioligand therapy that is in Phase 3 trials for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors; and PNT2004, a radioligand that targets fibroblast activation protein-a.

Recommended Story: Debt-To-Equity Ratio

Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter.